Growth hormone and IGF-I therapy in the hypercatabolic patient

S. E. Wolf, R. E. Barrow, D. N. Herndon

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

The use of exogenous GH to increase its circulating concentration, may benefit critically ill patients by increasing their nitrogen retention and promoting the wound healing process. GH also changes protein production in wounds, causes higher levels of insulin and changes substrate utilization. Its effects are anabolic, diabetogenic and lipolytic, acting through both direct and indirect mechanisms. The effects on carbohydrate and fat metabolism are directly mediated through specific GH receptors, while its effect on protein is mediated through IGF-I. Its effects on IGF-I production and the induction of IGF binding proteins are currently being studied in an effort to better understand the mechanism of GH actions during stress.

Original languageEnglish (US)
Pages (from-to)447-463
Number of pages17
JournalBailliere's Clinical Endocrinology and Metabolism
Volume10
Issue number3
DOIs
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Fingerprint Dive into the research topics of 'Growth hormone and IGF-I therapy in the hypercatabolic patient'. Together they form a unique fingerprint.

Cite this